Pillcheck Update 2024

To provide you with a lifetime of value from your Pillcheck, we’ve added more medications and the latest pharmacogenetics (PGx) guidelines. The current report may contain up to 256 drugs. However, the content of your report depends on when the sample was analyzed.

More medications

Up to 19 medications have been added across multiple treatment areas.

Generic Brand Name Treatment Area Conditions
Rolapitant Varubi Antiemetic Nausea
Darunavir Prezista Antiviral HIV
Nirmatrelvir and ritonavir Paxlovid Antiviral COVID-19 infection
Fluindione Previscan Cardiovascular Atrial fibrillation, deep vein thrombosis
Ivabradine Corlentor Cardiovascular Cardiomyopathies, hypertension
Nicardipine Cardene Cardiovascular Angina
Perampanel Fycompa Neurology Epilepsy
Triazolam Halcion Neurology Insomnia
Adagrasib Krazati Oncology Lung cancer
Everolimus Afinitor Oncology Breast, pancreatic cancers and autoimmune conditions
Sacituzumab govitecan Trodelvy Oncology Breast cancer, bladder cancer
Agomelatine Valdoxan Psychiatry Anxiety, depression
Asenapine Saphris Psychiatry Bipolar, schizophrenia
Buspirone BuSpar Psychiatry Anxiety disorders
Dapoxetine Priligy Psychiatry Premature ejaculation
Milnacipran Savella Psychiatry Fibromyalgia, major depressive disorder
Moclobemide Manerix Psychiatry Anxiety, depression
Viloxazine Qelbree Psychiatry ADHD
Ziprasidone Geodon Psychiatry Bipolar mania, schizophrenia

Show more

Clinical recommendations updated

Outcomes have been updated for the following drugs based on the latest pharmacogenetic science:

  • Alprazolam – recommendations are now based on two enzymes (CYP3A4 and CYP3A5)
  • Tolperisone – recommendations are now based on two enzymes (CYP2D6 and CYP2C19)
  • Tamoxifen – recommendations are now based on F2 and F5 carrier status in addition to CYP2D6 function to reflect the risk of thrombosis

FAQ


To provide customers with a lifetime of value from  Pillcheck, we’ve added more medications and the latest pharmacogenetics (PGx) guidelines. The current report may contain up to 256 drugs. However, the content of each report depends on when the sample was analyzed.

New drugs added based on Health Canada, FDA and EMA drug labels

Generic Brand Name Gene(s) Treatment Area Conditions
Rolapitant Varubi CYP3A4 Antiemetic Nausea
Darunavir Prezista CYP3A4 Antiviral HIV
Nirmatrelvir and ritonavir Paxlovid CYP2C19 Antiviral COVID-19 infection
Fluindione Previscan VKORC1 Cardiovascular Atrial fibrillation, deep vein thrombosis
Ivabradine Corlentor CYP3A4 Cardiovascular Cardiomyopathies, hypertension
Nicardipine Cardene CYP2C19 Cardiovascular Angina
Perampanel Fycompa CYP3A4 Neurology Seizures, epilepsy
Triazolam Halcion CYP3A4/5 Neurology Insomnia
Adagrasib Krazati CYP3A4 Oncology Lung cancer
Everolimus Afinitor, Certican CYP3A5 Oncology Breast, pancreatic cancers and autoimmune conditions
Sacituzumab govitecan Trodelvy UGT1A1 Oncology Breast cancer, bladder cancer
Agomelatine Valdoxan CYP1A2, CYP2C9 Psychiatry Anxiety, depression
Asenapine Saphris CYP1A2 Psychiatry Bipolar, schizophrenia
Buspirone BuSpar CYP3A4 Psychiatry Anxiety disorders
Dapoxetine Priligy CYP2D6 Psychiatry Premature ejaculation
Milnacipran Savella CYP3A4 Psychiatry Fibromyalgia, major depressive disorder
Moclobemide Manerix CYP2C19 Psychiatry Anxiety, depression
Viloxazine Qelbree CYP2D6 Psychiatry ADHD
Ziprasidone Geodon CYP3A4 Psychiatry Bipolar mania, schizophrenia

Clinical recommendations updated

Outcomes have been updated for the following drugs based on updated PGx guidelines and recent pharmacokinetic studies:

  • Alprazolam – combinatorial outcomes based on CYP3A4 and CYP3A5
  • Tolperisone – combinatorial outcomes based on CYP2D6 and CYP2C19
  • Tamoxifen – added F2 and F5 carrier status in addition to CYP2D6 function to reflect the risk of thrombosis

Contact us if you have any questions

    Skip to content